https://novapharmanews.com/us/news/fda-drug-approval-decisions-may-2026 2026-05-25T22:00:40.676Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z FDA Drug Approval Decisions Expected in May 2026: What to Anticipate https://novapharmanews.com/uploads/articles/fda-drug-approval-decisions-may-2026.webp FDA Drug Approval Decisions Expected in May 2026: What to Anticipate https://novapharmanews.com/eu/news/ireland-clinical-trials-eu-comparison 2026-05-25T22:20:27.111Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z Ireland's Clinical Trials: A Comparative Analysis with EU Peers https://novapharmanews.com/uploads/articles/ireland-clinical-trials-eu-comparison.webp Ireland's Clinical Trials: A Comparative Analysis with EU Peers https://novapharmanews.com/apac/news/datroway-approved-metastatic-tnbc 2026-05-25T21:31:14.456Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Datroway Approved: A New Hope for Metastatic TNBC Patients Datroway, oncology, breast cancer, metastatic triple-negative breast cancer https://novapharmanews.com/uploads/articles/datroway-approved-metastatic-tnbc.webp Datroway Approved: A New Hope for Metastatic TNBC Patients https://novapharmanews.com/apac/news/health-news-round-up-immunotherapy-pcos-clopidogrel-trials 2026-05-25T21:31:30.707Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Health News Round-Up: Immunotherapy, PCOS, and Clopidogrel Trials clopidogrel, depression, PCOS https://novapharmanews.com/uploads/articles/health-news-round-up-immunotherapy-pcos-clopidogrel-trials.webp Health News Round-Up: Immunotherapy, PCOS, and Clopidogrel Trials https://novapharmanews.com/eu/news/mayer-brown-serb-pharmaceuticals-idefirix-acquisition 2026-05-25T21:31:00.800Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z Mayer Brown Advises SERB Pharmaceuticals on Idefirix® Acquisition imlifidase, Idefirix https://novapharmanews.com/uploads/articles/mayer-brown-serb-pharmaceuticals-idefirix-acquisition.webp Mayer Brown Advises SERB Pharmaceuticals on Idefirix® Acquisition https://novapharmanews.com/apac/news/clinical-trials-day-2026-oncology-study-growth 2026-05-25T21:31:06.761Z NovaPharmaNews en-AU 2026-05-25T21:27:42.045Z Clinical Trials Day 2026: Oncology Study Growth Insights oncology https://novapharmanews.com/uploads/articles/clinical-trials-day-2026-oncology-study-growth.webp Clinical Trials Day 2026: Oncology Study Growth Insights https://novapharmanews.com/us/news/liminatus-pharma-innocsai-merger-market-analysis 2026-05-25T21:59:41.805Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z Liminatus Pharma to Merge with InnocsAI: A Market Analysis https://novapharmanews.com/uploads/articles/liminatus-pharma-innocsai-merger-market-analysis.webp Liminatus Pharma to Merge with InnocsAI: A Market Analysis https://novapharmanews.com/us/news/aurobindo-pharma-oai-classification-drug-approvals 2026-05-25T22:00:43.469Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z Aurobindo Pharma's OAI Classification: Implications for Drug Approvals https://novapharmanews.com/uploads/articles/aurobindo-pharma-oai-classification-drug-approvals.webp Aurobindo Pharma's OAI Classification: Implications for Drug Approvals https://novapharmanews.com/us/news/fda-approves-datopotamab-deruxtecan-dlnk-metastatic-tnbc 2026-05-25T21:59:41.834Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z FDA Approves Datopotamab deruxtecan-dlnk for Metastatic TNBC Datopotamab deruxtecan-dlnk, oncology, metastatic TNBC https://novapharmanews.com/uploads/articles/fda-approves-datopotamab-deruxtecan-dlnk-metastatic-tnbc.webp FDA Approves Datopotamab deruxtecan-dlnk for Metastatic TNBC https://novapharmanews.com/us/news/biomarin-swot-analysis-rare-disease-competitive-headwinds 2026-05-25T21:28:22.605Z NovaPharmaNews en-US 2026-05-25T21:27:42.045Z BioMarin's SWOT Analysis: Competitive Challenges Ahead rare disease https://novapharmanews.com/uploads/articles/biomarin-swot-analysis-competitive-challenges.webp BioMarin's SWOT Analysis: Competitive Challenges Ahead https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-05-25T21:31:16.928Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z CHMP May 2026 Output: A Shift in European Drug Development https://novapharmanews.com/uploads/articles/chmp-may-2026-output-shift-european-drug-development.webp CHMP May 2026 Output: A Shift in European Drug Development https://novapharmanews.com/eu/news/ema-approves-novo-wegovy-weight-loss-drug 2026-05-25T21:32:04.596Z NovaPharmaNews en-GB 2026-05-25T21:27:42.045Z EMA Approves Novo's Wegovy: A Game Changer in Weight Loss semaglutide, Wegovy, weight loss https://novapharmanews.com/uploads/articles/ema-approves-novo-wegovy-weight-loss-drug.webp EMA Approves Novo's Wegovy: A Game Changer in Weight Loss